Naomi Kiyota

Has grant

Associate Professor

Kobe University Hospital

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Naomi Kiyota is an Associate Professor at Kobe University Hospital in Japan. Her research primarily focuses on the management and treatment of head and neck cancers, including profiling adverse events related to chemoradiotherapy and investigating novel therapeutic approaches. She has contributed to various recent studies on topics such as the effects of acute kidney injury in postoperative patients and the adoption of electronic patient-reported outcome monitoring in cancer care.

Recent Grants

Grant: Close

National Cancer Center Research and Development Funds

Open Date: 2022-04-01

Close Date: 2023-03-31

Grant: Close

AMED

Open Date: 2022-04-01

Close Date: 2023-03-31

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (17)

Ryohei Sasaki

Professor

Kobe University Hospital

JAPAN

Naomi Kiyota

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (22)

Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review

Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT

Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors

Anticancer drug therapy for anaplastic thyroid cancer

Retrospective study of definitive therapy for head and neck mucosal melanoma: The RESUME study

The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery

Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial

Current status and future perspective of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck

Targeting Anterior Commissure Involvement with Hyperfractionated Radiotherapy for T1–T2 Squamous Cell Carcinoma of the Glottic Larynx

A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody

A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.

Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008

Serious Long-Term Effects of Head and Neck Cancer from the Survivors’ Point of View

Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer

Weekly versus 3‐weekly cisplatin along with radiotherapy for locoregionally advanced non‐nasopharyngeal head and neck cancers: Is the equipoise in literature addressed yet?

Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination

Reply to V. Noronha et al

Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial

Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib

A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial

Blowing time ratio and high-resolution manometry to evaluate swallowing function of patients with oral and oropharyngeal cancer

Collaborators (17)

Ryohei Sasaki

Hironobu Minami

Tomoya Yokota

Yoshinori Imamura

Yasuyuki Saito

Susanne Singer

Mizuo Ando

Andreas Boehm

Tetsuo Kondo

Ari Rosenberg

Mitsuhiro Ito

Sandra Nuyts

Koichiro Wasano

Yasushi Fujimoto

Sue S. Yom

Giuseppe Fanetti

Masato Nagaoka

Make your next move.